| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Supplement: n–3 Fatty Acids: Recommendations for Therapeutics and Prevention |
1 From Martek Biosciences Corporation, Columbia, MD (LMA and EBH), and the University of Maryland, Baltimore, MD (HO)
ABSTRACT
n–3 Fatty acids have important visual, mental, and cardiovascular health benefits throughout the life cycle. Biodistribution, interconversion, and dose response data are reviewed herein to provide a basis for more rational n–3 dose selections. Docosahexaenoic acid (DHA) is the principal n–3 fatty acid in tissues and is particularly abundant in neural and retinal tissue. Limited storage of the n–3 fatty acids in adipose tissue suggests that a continued dietary supply is needed. A large proportion of dietary 
-linolenic acid (ALA) is oxidized, and because of limited interconversion of n–3 fatty acids in humans, ALA supplementation does not result in appreciable accumulation of long-chain n–3 fatty acids in plasma. Eicosapentaenoic acid (EPA) but not DHA concentrations in plasma increase in response to dietary EPA. Dietary DHA results in a dose-dependent, saturable increase in plasma DHA concentrations and modest increases in EPA concentrations. Plasma DHA concentrations equilibrate in approximately 1 mo and then remain at steady state throughout supplementation. DHA doses of 
2 g/d result in a near maximal plasma response. Both dietary DHA and EPA reduce plasma arachidonic acid concentrations. Tissue contents of DHA and EPA also increase in response to supplementation with these fatty acids. Human milk contents of DHA are dependent on diet, and infant DHA concentrations are determined by their dietary intake of this fatty acid. We conclude that the most predictable way to increase a specific long-chain n–3 fatty acid in plasma, tissues, or human milk is to supplement with the fatty acid of interest.
Key Words: Docosahexaenoic acid • eicosapentaenoic acid • -linolenic acid • n–3 fatty acids • human dose response
This article has been cited by other articles:
|
|
 |
|
  J. Shannon, I. B King, J. W Lampe, D. L. Gao, R. M Ray, M.-G. Lin, H. Stalsberg, and D. B Thomas Erythrocyte fatty acids and risk of proliferative and nonproliferative fibrocystic disease in women in Shanghai, China Am. J. Clinical Nutrition, January 1, 2009; 89(1): 265 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Whelan Dietary Stearidonic Acid Is a Long Chain (n-3) Polyunsaturated Fatty Acid with Potential Health Benefits J. Nutr., January 1, 2009; 139(1): 5 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chung, J. A. Nettleton, R. N. Lemaitre, R. G. Barr, M. Y. Tsai, R. P. Tracy, and D. S. Siscovick Frequency and Type of Seafood Consumed Influence Plasma (n-3) Fatty Acid Concentrations J. Nutr., December 1, 2008; 138(12): 2422 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. L. Crowe, C. M. Skeaff, J. A. McMahon, S. M. Williams, and T. J. Green Lowering Plasma Homocysteine Concentrations of Older Men and Women with Folate, Vitamin B-12, and Vitamin B-6 Does Not Affect the Proportion of (n-3) Long Chain Polyunsaturated Fatty Acids in Plasma Phosphatidylcholine J. Nutr., March 1, 2008; 138(3): 551 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Kelley, D. Siegel, M. Vemuri, G. H. Chung, and B. E. Mackey Docosahexaenoic Acid Supplementation Decreases Remnant-Like Particle-Cholesterol and Increases the (n-3) Index in Hypertriglyceridemic Men J. Nutr., January 1, 2008; 138(1): 30 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Huang, J. T. Brenna, A. C. Chao, C. Tschanz, D. A. Diersen-Schade, and H.-C. Hung Differential Tissue Dose Responses of (n-3) and (n-6) PUFA in Neonatal Piglets Fed Docosahexaenoate and Arachidonoate J. Nutr., September 1, 2007; 137(9): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
